Skip to content
Screener

Vaxcyte, Inc. PCVX Net Change in Cash

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
Merck & Co. logo
Merck & Co.MRK
-$9.29B-103%
Moderna logo
ModernaMRNA
-$185M+46.4%
Novavax logo
NovavaxNVAX
-$36.89M-288%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$5.01M+114%
Regenxbio logo
RegenxbioRGNX
$21.26M

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$8.07B+89.7%
Enterprise value$7.93B+96.5%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001649094-26-000017
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Taxes paid related to the net share settlement of equity awards(9,295)(5,290)
Net cash provided by financing activities601,583759
Effect of exchange rate changes on cash and cash equivalents(664)1,172
Net increase (decrease) in cash, cash equivalents and restricted cash86,884(41,026)
Cash, cash equivalents and restricted cash, beginning of period175,425389,195
Cash, cash equivalents and restricted cash, end of period$262,309$348,169
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents$260,843$346,850

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s net change in cash?
Vaxcyte, Inc. (PCVX) reported net change in cash of $86.88M in Q1 2026.
How has Vaxcyte, Inc.'s net change in cash changed year-over-year?
Vaxcyte, Inc.'s net change in cash increased by 311.8% year-over-year, from -$41.03M to $86.88M.
What is the long-term trend for Vaxcyte, Inc.'s net change in cash?
Over 3 years (2021 to 2025), Vaxcyte, Inc.'s net change in cash has grown at a -12.2% compound annual growth rate (CAGR), from -$316.34M to -$213.77M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Vaxcyte, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude